Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients.

Reed, Daniel R; Sen, Jeremy M; Pierce, Eric J; Elsarrag, Ramey Z; K Keng, Michael

Reed, Daniel R; Sen, Jeremy M; Pierce, Eric J; Elsarrag, Ramey Z; K Keng, Michael.

Afiliação

Reed DR; Division of Hematology/Oncology, Department of Medicine, University of Virginia, Charlottesville, USA.
Sen JM; Department of Pharmacy Services, University of Virginia, Charlottesville, USA.
Pierce EJ; Department of Medicine, University of Virginia, Charlottesville, USA.
Elsarrag RZ; School of Medicine, University of Virginia, Charlottesville, USA.
K Keng M; Division of Hematology/Oncology, Department of Medicine, University of Virginia, Charlottesville, USA.

J Oncol Pharm Pract ; 26(5): 1200-1212, 2020 Jul.

Article em En | MEDLINE | ID: mdl-32338136

Assuntos

Compostos de Anilina/administração & dosagem; Leucemia Mieloide Aguda/tratamento farmacológico; Inibidores de Proteínas Quinases/uso terapêutico; Pirazinas/administração & dosagem; Humanos; Mutação; Tirosina Quinase 3 Semelhante a fms/genética

Palavras-chave

FMS-like tyrosine kinase 3; Targeted oncology; Xospata; gilteritinib; relapsed/refractory acute myeloid leukemia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazinas / Leucemia Mieloide Aguda / Inibidores de Proteínas Quinases / Compostos de Anilina Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google